Cervical Intraepithelial Neoplasia
Conditions
Brief summary
Indirect comparisons were performed using data from GOG-0179 versus GOG-0169 to permit comparison of topotecan in combination with cisplatin versus cisplatin plus paclitaxel via the common comparator of cisplatin monotherapy. Both GOG-0179 and GOG-0169 were conducted in patients with stage IVB, recurrent or persistent carcinoma of the cervix, but there were some differences between the respective study populations. Patients with prior chemotherapy were eligible for GOG-0179 but ineligible for GOG-0169 (except when chemotherapy was used for radiation sensitisation). Fewer patients had received chemotherapy as a radiosensitiser in GOG-0169 (27%) than in GOG-0179 (\ 60%) and these patients were unevenly distributed between treatment arms in GOG-0169. In addition, the proportion of patients receiving cisplatin as a radiosensitiser in GOG-0169 is unknown. For these reasons, there are limitations associated with the indirect meta-analysis.
Interventions
DRUGcisplatin
50 mg/m2 IV cisplatin on day 1 and then every 3 weeks for 6 courses
DRUGtopotecan
topotecan 0.75 mg/m2 on days 1, 2, and 3. The regimen was repeated every 3 weeks for 6 courses
DRUGpaclitaxel
135 mg/m2 paclitaxel on day 1 and then every 3 weeks for 6 courses
Sponsors
GlaxoSmithKline
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* randomised clinical trials, or systematic reviews and meta-analyses * treatment with topotecan or platinum-based single and combination regimens in female patients of any race with cancer of the cervix recurrent after radiotherapy or stage IVB disease
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | 12 months |
Outcome results
None listed